Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 77, Issue 3, 2006, Pages 390-392

  Czaplinski, A ^a   Yen, A A ^b   Appel, S H ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RILUZOLE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; APPEL ALS SCORE; ARTICLE; COHORT ANALYSIS; DISEASE COURSE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVOUS SYSTEM PARAMETERS; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SCORING SYSTEM; SURVIVAL RATE; TRACHEOSTOMY;

ADULT; AGED; COHORT STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MOTOR NEURON DISEASE; MUSCLE WEAKNESS; PROGNOSIS; RESPIRATORY MUSCLES; TEXAS; TRACHEOSTOMY; VITAL CAPACITY;

EID: 33644546709     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2005.072660     Document Type: Article

References (24)

1. Traynor BJ, Zhang H, Shefner JM, et al. Functional outcome measures as clinical trial endpoints in ALS. Neurology 2004;63:1933-5.
2. Caroscio JT, Mulvihill MN, Sterling R, et al. Amyotrophic lateral sclerosis: its natural history. Neurol Clin 1987;5:1-8.
3. Kleopa KA, Sherman M, Neal B, et al. Bipap improves survival and rate of pulmonary function decline in patients with ALS. J Neurol Sci 1999;164:82-8.
4. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995;118:707-19.
5. Miller RG, Munsat TL, Swash M, et al. Consensus guidelines for the design and implementation of clinical trials in ALS. J Neurol Sci 1999;169:2-12.
6. Jackson CE, Rosenfeld J, Moore DH, et al. A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients. J Neurol Sci 2001;191:75-8.
7. Schiffman PL, Belsh JM. Pulmonary function at diagnosis of amyotrophic lateral sclerosis. Chest 1993;103:508-13.
8. Brinkmann JR, Andres P, Mendoza M, et al. Guidelines for the use and performance of quantitative outcome measures in ALS clinical trials. J Neurol Sci 1997;147:97-111.
9. Ringel SP, Murphy JR, Alderson MK, et al. The natural history of amyotrophic lateral sclerosis. Neurology 1993;43:1316-22.
10. Gay PC, Westbrook PR, Daube JR, et al. Effets of alterations in pulmonary function and sleep variables on survival in patients with amyotrophic lateral sclerosis. Mayo Clin Proc 1991;66:686-94.
11. Kaplan LM, Hollander D. Respiratory dysfunction in amyotrophic lateral sclerosis. Clin Chest Med 1994;15:675-81.
12. Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 2003;61:456-64.
13. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330:585-91.
14. Stambler N, Charatan M, Cedarbaum JM. Prognostic indicators of survival in ALS. Neurology 1998;50:66-72.
15. Moore DH, Miller RG, WALS Study Group, ALS CARE Study Group. ALSRFS as a measure of disease progression and survival. The Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4(suppl 1):42.
16. Kaufmann P, Levy G, Thompson JL, et al. The ALSFRSr predicts survival time in an ALS clinic population. Neurology 2005;64:38-43.
17. Chio A, Mora G, Leone M, et al. Piemonte and Volle d'Aosta Register for ALS (PARALS). Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology 2002;59:99-103.
18. Magnus T, Beck M, Giess R, et al. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve 2002;25:709-14.
19. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994;124:96-107.
20. Traynor BJ, Codd MB, Corr B, et al. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study. Arch Neurol 2000;57:1171-6.
21. Lange DJ, Murphy PL, Diamond B, et al. Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch Neurol 1998;55:93-6.
22. Yen AA, Simpson E, Haverkamp LJ, et al. AALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5(suppl 1):S1-S5.
23. Appel V, Stewart SS, Smith G, et al. A rating scale for amyotrophic lateral sclerosis: Description and preliminary experience. Ann Neurol 1987;22:328-33.
24. Lee JR, Annegers JF, Appel SH. Prognosis of amyotrophic lateral sclerosis and the effect of referral selection. J Neurol Sci 1995;132:207-15.